Dynamic Cell Therapies

Dynamic Cell Therapies (DCT) is preclinical stage biotech company developing two platforms: redirectable CAR T-cells and private cytokine signaling systems licensed from the Dana-Farber Cancer Institute.

The company has shown improved efficacy of CAR T-therapies in both in vitro and in vivo multiple myeloma models.